ADAGIO THERAPEUTICS, INC.

(ADGI)
  Report
Delayed Nasdaq  -  04:00 2022-08-19 pm EDT
4.200 USD   -6.87%
08/19INSIDER BUY : Adagio Therapeutics
MT
08/15ADAGIO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
08/15Adagio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Adagio Therapeutics, Inc. Elects Class I Directors

06/22/2022 | 05:18pm EDT

Adagio Therapeutics, Inc. held its Annual Meeting of Stockholders on June 22, 2022, elected Tamsin Berry, Marc Elia and Clive Meanwell as Class I directors, each to serve for a three-year term expiring at the 2025 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified.


© S&P Capital IQ 2022
All news about ADAGIO THERAPEUTICS, INC.
08/19INSIDER BUY : Adagio Therapeutics
MT
08/15ADAGIO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
08/15Adagio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Month..
CI
08/15ADAGIO THERAPEUTICS : Reports Second Quarter 2022 Financial Results and Business Highlight..
PU
08/15Adagio Therapeutics Q2 Net Loss Narrows
MT
08/15Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highligh..
GL
07/05ADAGIO THERAPEUTICS : Announces Results of Annual Meeting of Stockholders and Evolution of..
PU
07/05ADAGIO THERAPEUTICS, INC. : Change in Directors or Principal Officers, Other Events, Finan..
AQ
07/05SECTOR UPDATE : Health Care Stocks Struggle Tuesday
MT
07/05SECTOR UPDATE : Health Care Stocks Retreating in Tuesday Trade
MT
More news
Analyst Recommendations on ADAGIO THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -262 M - -
Net cash 2022 381 M - -
P/E ratio 2022 -1,75x
Yield 2022 -
Capitalization 457 M 457 M -
EV / Sales 2022 -
EV / Sales 2023 27,6x
Nbr of Employees 102
Free-Float 66,6%
Chart ADAGIO THERAPEUTICS, INC.
Duration : Period :
Adagio Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAGIO THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 4
Last Close Price 4,20 $
Average target price 3,83 $
Spread / Average Target -8,73%
EPS Revisions
Managers and Directors
David Hering Chief Executive Officer & Director
Jane Pritchett V. Henderson Chief Financial & Business Officer
Marc W. Elia Chairman
Laura Walker Chief Scientific Officer
Rebecca L. Dabora Chief Technology & Manufacturing Officer
Sector and Competitors
1st jan.Capi. (M$)
ADAGIO THERAPEUTICS, INC.-42.15%457
GILEAD SCIENCES, INC.-10.01%81 694
VERTEX PHARMACEUTICALS36.17%75 473
REGENERON PHARMACEUTICALS, INC.-2.08%66 800
WUXI APPTEC CO., LTD.-23.76%38 898
BIONTECH SE-42.74%35 872